natgillin/translations-raw huggingface dataset:
at least 10 to &lt; 15 kg
Najmanje 10 do &lt; 15 kg
at least 15 to &lt; 25 kg
Najmanje 15 do &lt; 25 kg
at least 25 to &lt; 35 kg
Najmanje 25 do &lt; 35 kg
at least 5 to &lt; 10 kg (REYATAZ
najmanje 5 do &lt; 10 kg
at least 5 to &lt; 10 kg (REYATAZ
Najmanje 5 do &lt; 10 kg (REYATAZ
at least 5 to &lt; 10 kg (REYATAZ
Najmanje 5 to &lt; 10 kg (REYATAZ
At low concentrations ( &lt; 100 micrograms/ml), approximately 90% of salicylic acid is bound to albumin.
Pri niskim koncentracijama ( &lt; 100 µg/ml), otprilike 90% salicilatne kiseline vezano je za albumin.
At low concentrations ( &lt; 100 micrograms/ml), approximately 90% of salicylic acid is bound to albumin.
Pri niskim koncentracijama ( &lt; 100 μg/ml), otprilike 90% salicilatne kiseline vezano je za albumin.
At one year the overall RFS was significantly better for Glivec (97.7%) vs. placebo (82.3%), (p &lt; 0.0001).
Nakon jedne godine ukupno preživljenje bez recidiva bolesti bilo je značajno bolje za Glivec (97,7%) u odnosu na placebo (82,3%), (p &lt; 0,0001).
At poorly tolerated doses in rats and dogs ( &gt; 10 or 7 times the human clinical exposure in adult or paediatric ITP patients at 75 mg/day and &gt; 4 times the human clinical exposure in HCV patients at 100 mg/day, based on AUC), decreased reticulocyte counts and regenerative bone marrow erythroid hyperplasia (rats only) were observed in short term studies.
U slabo podnošljivim dozama u štakora i pasa ( &gt; 10 ili 7 puta kliničke izloženosti odraslih ili pedijatrijskih bolesnika s ITP-om pri dozi od 75 mg/dan i &gt; 4 puta kliničke izloženosti bolesnika s HCV-om pri dozi od 100 mg/dan, mjereno AUC-om) zabilježeni su smanjen broj retikulocita i regenerativna eritroidna hiperplazija koštane srži (samo u štakora) tijekom kratkoročnih studija.
At present, insufficient data in patients with a diastolic blood pressure &gt; 100 mmHg prior to thrombolytic therapy are available for reteplase.
Trenutno nema dovoljno podataka o primjeni retaplaze u bolesnika s dijastoličkim tlakom &gt; 100 mmHg prije trombolitičkog liječenja.
At steady state, the systemic exposures in paediatric patients weighing 10–20 kg, 20–40 kg and &gt; 40 kg were 43%, 67% and 75%, respectively, of the adult systemic exposure.
U stanju dinamičke ravnoteže, sistemske izloženosti pedijatrijskih bolesnika koji su težili 10–20 kg, 20-40 kg i &gt; 40 kg iznosile su 43%, 67%, odnosno 75% sistemske izloženosti kod odraslih.
At the 12-week primary endpoint (24-hour trough FEV1), the 150 microgram dose resulted in a 130-180 ml increase compared to placebo (p &lt; 0.001) and a 60 ml increase compared to salmeterol 50 microgram twice a day (p &lt; 0.001).
Kao primarni ishod nakon 12 tjedana (24- satni najniži FEV1), doza od 150 mikrograma dovela je do povećanja od 130-180 ml u usporedbi s placebom (p &lt; 0,001) te povećanje od 60 ml u usporedbi sa salmeterolom u dozi od 50 mikrograma dva puta na dan (p &lt; 0,001).
At the 18 month endpoint, FORSTEO significantly increased lumbar spine BMD (7.2 %) compared with alendronate (3.4 %) (p &lt; 0.001).
U ishodu nakon 18 mjeseci FORSTEO je značajno povećao BMD lumbalnog dijela kralježnice (7,2%) u usporedbi s alendronatom (3,4%) (p &lt; 0,001).
At the 20 mg dose Levitra film-coated tablets, elderly (≥ 65 years old) patients had higher frequencies of headaches (16.2% versus 11.8%) and dizziness (3.7% versus 0.7%) than younger patients ( &lt; 65 years old).
Uz Levitra filmom obložene tablete od 20 mg, stariji (u dobi od ≥ 65 godina) bolesnici imali su veću učestalost glavobolja (16,2% nasuprot 11,8%) i omaglice (3,7% nasuprot 0,7%) nego mlađi bolesnici (u dobi od &lt; 65 godina).
At the 20 mg dose Vivanza film-coated tablets, elderly (≥ 65 years old) patients had higher frequencies of headaches (16.2% versus 11.8%) and dizziness (3.7% versus 0.7%) than younger patients ( &lt; 65 years old).
Uz Vivanza filmom obložene tablete od 20 mg, stariji (u dobi od ≥ 65 godina) bolesnici imali su veću učestalost glavobolja (16,2% nasuprot 11,8%) i omaglice (3,7% nasuprot 0,7%) nego mlađi bolesnici (u dobi od &lt; 65 godina).
At the 20 mg dose Vivanza film-coated tablets, elderly ( 65 years old) patients had higher frequencies of headaches (16.2% versus 11.8%) and dizziness (3.7% versus 0.7%) than younger patients ( &lt; 65 years old).
Uz Vivanza filmom obložene tablete od 20 mg, stariji (u dobi od ≥ 65 godina) bolesnici imali su veću učestalost glavobolja (16,2% nasuprot 11,8%) i omaglice (3,7% nasuprot 0,7%) nego mlađi bolesnici (u dobi od &lt; 65 godina).
At the end of 24 weeks post-treatment follow-up, mean decrease from baseline in weight and height percentiles were still 3 percentiles and 7 percentiles, respectively, and 20% of the children continued to have inhibited growth (growth velocity &lt; 3rd percentile).
Na kraju 24-tjednog praćenja nakon završetka liječenja srednje vrijednosti su još uvijek bile smanjene u odnosu na početak ispitivanja za prosječno 3 percentila na krivulji težine te za prosječno 7 percentila na krivulji rasta, dok je 20% djece i dalje imalo usporen rast (brzina rasta &lt; 3. percentile).
At the end of the maintenance treatment an improvement of at least 30% was seen in 57% and 55% of the subjects receiving rotigotine 8 mg/24 h and 12 mg/24 h, respectively and in 34% of the subjects receiving placebo (Differences 22% and 21%, respectively, CI95% 10%; 35% and 8%; 33%, respectively, p &lt; 0.001 for both rotigotine groups).
Na kraju terapije održavanja poboljšanje od najmanje 30% zabilježeno je u 57%, odnosno 55% ispitanika koji su primali rotigotin 8 mg/24 h, odnosno 12 mg/24 h te u 34% ispitanika koji su primali placebo (razlike 22%, odnosno 21%; CI95%: 10%, 35%, odnosno 8%, 33%; p &lt; 0,001 za obje rotigotin-skupine).
At the end of the maintenance treatment an improvement of at least 30% was seen in 57% and 55% of the subjects receiving rotigotine 8 mg/24 h and 12 mg/24 h, respectively and in 34% of the subjects receiving placebo (Differences 22% and 21%, respectively, CI95% 10%; 35% and 8%; 33%, respectively, p &lt; 0.001 for both rotigotine groups).
Na kraju terapije održavanja, poboljšanje od najmanje 30% zabilježeno je u 57%, odnosno 55% ispitanika koji su primali rotigotin 8 mg/24 h, odnosno 12 mg/24 h te u 34% ispitanika koji su primali placebo (razlike 22%, odnosno 21%, CI95%: 10%; 35%, odnosno 8%; 33%; p &lt; 0,001 za obje rotigotin-skupine).
At the end of the maintenance treatment an improvement of at least 30% was seen in 57% and 55% of the subjects receiving rotigotine 8 mg/24 h and 12 mg/24 h, respectively and in 34% of the subjects receiving placebo (Differences 22% and 21%, respectively, CI95% 10%; 35% and 8%; 33%, respectively, p &lt; 0.001 for both rotigotine groups).
Na kraju terapije održavanja, poboljšanje od najmanje 30% zabilježeno je u 57%, odnosno 55% ispitanika koji su primali rotigotin 8 mg/24 h, odnosno 12 mg/24 h te u 34% ispitanika koji su primali placebo (razlike 22%, odnosno 21%; CI95%: 10%, 35%, odnosno 8%, 33%; p &lt; 0,001 za obje skupine rotigotin-skupine).
At the end of week 24, 93 patients on hemodialysis whose serum phosphorus levels were controlled ( &lt; 1.78 mmol/L) with Velphoro in the first part of the study, were re-randomized to continue treatment with either their week 24 maintenance dose (N=44 or a non-effective low dose control 250 mg/day, N=49) of Velphoro for a further 3 weeks.
Po završetku 24. tjedna, 93 bolesnika na hemodijalizi, čije su razine fosfora u serumu bile kontrolirane ( &lt; 1,78 mmol/l) lijekom Velphoro u prvom dijelu ispitivanja, ponovno su randomizirana da bi u naredna 3 tjedna nastavili terapiju njihovom dozom održavanja iz 24. tjedna (n=44) ili neučinkovitom niskom kontrolnom dozom lijeka Velphoro (250 mg/dan, n=49).
At the final analysis, the ORR as determined by the investigator’s assessment was 46% (95% CI: 41 - 51) for the sunitinib arm and 12.0% (95% CI: 9 - 16) for the IFN-α arm (p &lt; 0.001).
U završnoj je analizi ORR prema procjeni ispitivača iznosio 46% (95% CI: 41-51) u skupini liječenoj sunitinibom te 12,0% (95% CI: 9-16) u skupini koja je primala IFN-α (p &lt; 0,001).
At the last visit, the increase in 6MWD in patients treated with riociguat was 46 m (95% confidence interval (CI): 25 m to 67 m; p &lt; 0.0001), compared to placebo.
Na posljednjem posjetu, 6MWD u bolesnika liječenih riocigvatom povećao se za 46 m (95% interval pouzdanosti (CI): 25 m do 67 m; p &lt; 0,0001) u usporedbi s placebom.
At the pre-specified analysis with a 19 December 2011 data cut, a significant improvement in the primary endpoint of PFS (HR = 0.30; 95% Cl 0.18, 0.51; p &lt; 0.0001) was achieved.
U prethodno određenoj analizi s podacima zaključenim 19. prosinca 2011., dosegnuto je značajno poboljšanje primarnog ishoda PFS (HR=0,30; 95% CI 0,18; 0,51; p &lt; 0,0001).
At the pre-specified interim analysis for overall survival when 540 deaths were observed, treatment with enzalutamide demonstrated a statistically significant improvement in overall survival compared to treatment with placebo with a 29.4% reduction in risk of death [HR = 0.706, (95% CI: 0.596; 0.837), p &lt; 0.0001].
U vrijeme unaprijed planirane interim analize ukupnog preživljenja nakon 540 smrti, liječenje enzalutamidom pokazalo je statistički značajno povećanje ukupnog preživljenja u usporedbi s placebom, sa smanjenjem rizika od smrti za 29,4% [HR = 0,706, (95% CI: 0,596; 0,837), p &lt; 0,0001].
At the pre-specified interim analysis with a December 30, 2010 data cut-off, significant improvements in the co-primary endpoints of OS (p &lt; 0.0001) and PFS (p &lt; 0.0001) (unstratified log-rank test) were observed.
U prethodno planiranoj međuanalizi podataka prikupljenih do 30. prosinca 2010. opažena su značajna poboljšanja u obje primarne mjere ishoda: OS (p &lt; 0,0001) i PFS (p &lt; 0,0001) (nestratificirani log- rank test).
At the pre-specified rPFS analysis, a statistically significant improvement was demonstrated between the treatment groups with an 81.4% reduction in risk of radiographic progression or death [HR = 0.186 (95% CI: 0.149, 0.231), p &lt; 0.0001].
U unaprijed planiranoj analizi rPFS-a, pokazano je statistički značajno poboljšanje između ispitivanih skupina s 81,4%-tnim smanjenjem rizika od radiografske progresije ili smrti HR = 0,186 (95% CI: 0,149; 0,231), p &lt; 0,0001].
At the time of the final PFS analysis (with median follow-up of 2.64 years), the overall survival data were not mature and there was no significant difference between treatment groups in the HER2- positive population; this had not changed with additional follow-up ( &gt; 7.5 years median follow-up time; Table 7).
U trenutku završne analize PFS-a (s medijanom praćenja od 2,64 godine), podaci o ukupnom preživljenju nisu bili potpuni i nije bilo značajne razlike između liječenih skupina u HER2 pozitivnoj populaciji; to se nije promijenilo s dodatnim praćenjem (medijan vremena praćenja bio je &gt; 7,5 godina; Tablica 7).
At the time of the long-term biopsy, all patients had HBV DNA &lt; 300 copies/ml and 49/57 (86%) had serum ALT ≤ 1 times ULN.
U vrijeme biopsije jetre, svi su bolesnici imali HBV DNK &lt; 300 kopija/ml, a 49/57 (86%) imalo je serumsku ALT ≤ 1 puta iznad GGN.
At two years 93.4 % (p &lt; 0.001) of patients receiving Bonviva 150 mg once monthly and 78.4 %, of patients receiving ibandronic acid 2.5 mg daily had total hip BMD increases above or equal to baseline.
Nakon dvije godine je u 93,4% (p &lt; 0,001) bolesnika koji su primali lijek Bonviva 150 mg jedanput mjesečno odnosno 78,4% bolesnika koji su primali ibandronatnu kiselinu 2,5 mg jedanput dnevno došlo do povećanja BMD cijelog kuka više ili jednako početnoj razini.
At two years 93.4 % (p &lt; 0.001) of patients receiving ibandronic acid 150 mg once monthly and 78.4 %, of patients receiving ibandronic acid 2.5 mg daily had total hip BMD increases above or equal to baseline.
Nakon dvije godine je u 93,4% (p &lt; 0,001) bolesnika koji su primali ibandronatnu kiselinu 150 mg jedanput mjesečno odnosno 78,4% bolesnika koji su primali ibandronatnu kiselinu 2,5 mg jedanput dnevno došlo do povećanja BMD cijelog kuka više ili jednako početnoj razini.
At two years, 87.1 % (p &lt; 0.001) and 70.5 %,of patients met this criterion in the 150 mg monthly and 2.5 mg daily arms respectively.
Nakon dvije godine taj je kriterij zadovoljilo 87,1% (p &lt; 0,001) bolesnika u skupini 150 mg jedanput mjesečno odnosno 70,5% bolesnika u skupini 2,5 mg jedanput dnevno.
At two years, glycaemic control (defined as HbA1c &lt; 8.0%) was sustained in 69% of patients treated with pioglitazone, compared with 50% of patients on gliclazide.
Nakon dvije godine, kontrola glikemije (definirana kao HbA1c &lt; 8,0%) bila je održana u 69% bolesnika liječenih pioglitazonom u odnosu na 50% bolesnika koji su uzimali gliklazid.
At week 12 (before dose adjustment), 65.2% of patients treated with alirocumab 300 mg Q4W reached an LDL-C of ˂70 mg/dL as compared to 2.8% in the placebo group.
U 12. tjednu (prije prilagodbe doze), 65,2% bolesnika liječenih s 300 mg alirokumaba svaka 4 tjedna doseglo je LDL-C vrijednost &lt; 70 mg/dl u usporedbi s 2,8% u placebo skupini.
At week 12 (before dose adjustment), 77.3% of patients treated with alirocumab 300 mg Q4W reached an LDL-C of ˂70 mg/dL as compared to 9.3% in the placebo group.
U 12.tjednu (prije prilagodbe doze), 77,3% bolesnika liječenih s 300 mg alirokumaba svaka 4 tjedna doseglo je vrijednost LDL-C &lt; 70 mg/dl u usporedbi s 9,3% u placebo skupini.
At week 12 (before up-titration), 34.9% of patients reached an LDL-C of ˂70 mg/dL (˂1.81 mmol/L) as compared to 0% in the ezetimibe group.
Vrijednost LDL-C od &lt; 70 mg/dl ( &lt; 1,81 mmol/l) je u 12. tjednu (prije postupnog povećanja doze) postiglo 34,9% bolesnika liječenih alirokumabom usporedbi sa 0% bolesnika koji su primali ezetimib.
At week 12 (before up-titration), 76.0% of patients in the alirocumab group reached an LDL-C of ˂70 mg/dL (˂ 1.81 mmol/L) as compared to 11.3% in the placebo group.
Vrijednost LDL-C od &lt; 70 mg/dl ( &lt; 1,81 mmol/l) je u 12. tjednu (prije postupnog povećanja doze) postiglo 76,0% bolesnika liječenih alirokumabom u usporedbi sa 11,3% bolesnika koji su primali placebo.
At week 12 and 24 improvements in parameters of peripheral activity characteristic of psoriatic arthritis (e.g. number of swollen joints, number of painful/tender joints, dactylitis and enthesitis) were seen in the Cimzia-treated patients (nominal p-value p &lt; 0.01).
U 12. i 24. tjednu u bolesnika liječenih Cimzijom (nominalna p-vrijednost p &lt; 0,01) zabilježena su poboljšanja u parametrima periferne aktivnosti karakteristične za psorijatični artritis (npr. broj otečenih zglobova, broj bolnih/osjetljivih zglobova, daktilitis i entesitis).
At week 12, 82.1% of patients in the alirocumab group reached an LDL-C ˂70 mg/dL (˂1.81 mmol/L) compared to 7.2% of patients in the placebo group.
Vrijednost LDL-C od &lt; 70 mg/dl ( &lt; 1,81 mmol/l) je u 12. tjednu postiglo 82,1% bolesnika liječenih alirokumabom u odnosu na 7,2% bolesnika koji su primali placebo.
At week 12, the number of BASDAI 50 responders were 3/35 (9%) in the placebo group, and 20/35 (57%) in the 5 mg/kg group (p &lt; 0.01).
12. tjednu, klinički odgovor BASDAI 50 imalo je 3 od 35 (9%) bolesnika u skupini koja je primala placebo i 20 od 35 (57%) bolesnika u skupini koja je primala infliksimab u dozi od 5 mg/kg (p &lt; 0,01).
At week 12, the number of BASDAI 50 responders were 3/35 (9%) in the placebo group, and 20/35 (57%) in the 5 mg/kg group (p &lt; 0.01).
U 12. tjednu, klinički odgovor BASDAI 50 imalo je 3 od 35 (9%) bolesnika u skupini koja je primala placebo i 20 od 35 (57%) bolesnika u skupini koja je primala infliksimab u dozi od 5 mg/kg (p &lt; 0,01).
At week 12, the proportion of tocilizumab treated patients showing a minimally clinically important improvement in the Childhood Health Assessment Questionnaire – Disability Index (defined as an individual total score decrease of ≥ 0.13) was significantly higher than in placebo treated patients, 77% versus 19% (p &lt; 0.0001).
Udio bolesnika liječenih tocilizumabom koji su nakon 12 tjedana pokazivali minimalno klinički značajno poboljšanje prema Upitniku za procjenu zdravlja djece – indeksu onesposobljenosti (definirano kao pojedinačno smanjenje ukupne ocjene ≥ 0,13) bio je značajno veći od udjela bolesnika koji su primali placebo, odnosno 77% naspram 19% (p &lt; 0,0001).
At week 24 2.8 &lt; 0.0001 1.9 (1.8, 3.7) (0.9, 2.9)
U 24. tjednu 2,8 &lt; 0,0001 1,9 0,0004 (1,8; 3,7) (0,9; 2,9)
At week 24 the time-weighted average change from baseline in log10 plasma HIV-1 RNA levels (DAVG24) was -0.03 log10 copies/ml and -0.61 log10 copies/ml for the placebo and tenofovir disoproxil 245 mg (as fumarate) recipients (p &lt; 0.0001).
U 24. tjednu vremenski ponderirana prosječna promjena od početne vrijednosti izražena kao log10 koncentracije HIV-1 RNK (DAVG24) u plazmi iznosila je -0,03 log10 kopija/ml za primatelje placeba i -0,61 log10 kopija/ml za primatelje tenofovirdizoproksila u dozi od 245 mg (u obliku tenofovirdizoproksilfumarata) (p &lt; 0,0001).
At week 24, a significant reduction in DAS28 from baseline (mean improvement) of 3.5 was observed on both treatment arms, and a comparable proportion of patients had achieved DAS28 clinical remission (DAS28 &lt; 2.6) on the subcutaneous (38.4%) and IV (36.9%) arms.
24 tjedna u obje je skupine primijećeno značajno smanjenje vrijednosti DAS28 (srednje poboljšanje) od 3,5 u odnosu na početnu vrijednost, a udio bolesnika koji su postigli kliničku remisiju prema DAS28 (DAS28 &lt; 2,6) bio je usporediv u skupini koja je primala supkutanu formulaciju (38,4%) i onoj koja je primala intravensku formulaciju (36,9%).
At week 24, a significant reduction in DAS28 from baseline of 3.1 was observed on subcutaneous and 1.7 on placebo arm, and for DAS28 &lt; 2.6, 32.0% was observed on subcutaneous and 4.0% on placebo arm.
Nakon 24 tjedna u bolesnika liječenih supkutanom formulacijom zabilježeno je značajno smanjenje vrijednosti DAS28 za 3,1 u odnosu na početnu vrijednost, a za 1,7 u bolesnika koji su primali placebo, dok je vrijednost DAS28 &lt; 2,6 primijećena u 32,0% bolesnika liječenih supkutanom formulacijom te u 4,0% bolesnika koji su primali placebo.
At week 24, the number of ASAS 20 responders was 15/78 (19%) in the placebo group, and 123/201 (61%) in the 5 mg/kg infliximab group (p &lt; 0.001).
U 24. tjednu, klinički odgovor ASAS 20 imalo je 15 od 78 (19%) bolesnika u skupini koja je primala placebo i 123 od 201 (61%) bolesnika u skupini koja je primala infliksimab u dozi od 5 mg/kg (p &lt; 0,001).
At Week 26, the mean percent change in LDL-C from baseline of LDL-C was -40% (p &lt; 0.001) in the Intent to Treat (ITT) population.
U 26. tjednu, u populaciji predviđenoj za liječenje (ITT) srednja vrijednost postotka promjene vrijednosti LDL kolesterola u odnosu na početnu vrijednost LDL kolesterola iznosila je -40% (p &lt; 0,001).
At week 26, Ultibro Breezhaler produced statistically significant improvement in peak FEV1 compared to placebo in the first 4 hours post dose (330 ml) (p &lt; 0.001).
U 26. tjednu Ultibro Breezhaler proizveo je statistički značajno poboljšanje vršnog FEV1 u usporedbi s placebom u prva 4 sata nakon doze (330 ml) (p &lt; 0,001).
At week 26, Ulunar Breezhaler produced statistically significant improvement in peak FEV1 compared to placebo in the first 4 hours post dose (330 ml) (p &lt; 0.001).
U 26. tjednu Ulunar Breezhaler proizveo je statistički značajno poboljšanje vršnog FEV1 u usporedbi s placebom u prva 4 sata nakon doze (330 ml) (p &lt; 0,001).
At week 26, Xoterna Breezhaler produced statistically significant improvement in peak FEV1 compared to placebo in the first 4 hours post dose (330 ml) (p &lt; 0.001).
U 26. tjednu Xoterna Breezhaler proizveo je statistički značajno poboljšanje vršnog FEV1 u usporedbi s placebom u prva 4 sata nakon doze (330 ml) (p &lt; 0,001).
At week 48 the proportion of subjects with HIV RNA &lt; 50 copies/ml were 63 %, 80 % and 86 % for the ZDV/3TC/ABC, ZDV/3TC/EFV and ZDV/3TC/ABC/EFV arms, respectively.
U 48. tjednu, udio ispitanika s HIV RNA &lt; 50 kopija/ml, slijedom navođenja bio je 63%, 80% i 86% za terapijske skupine ZDV/3TC/ABC, ZDV/3TC/EFV i ZDV/3TC/ABC/EFV.
At week 48 the proportion of subjects with HIV RNA &lt; 50 copies/ml were 63%, 80% and 86% for the ZDV/3TC/ABC, ZDV/3TC/EFV and ZDV/3TC/ABC/EFV arms, respectively.
U 48. tjednu je HIV RNK &lt; 50 kopija/ml imalo 63% bolesnika koji su uzimali ZDV/3TC/ABC, 80% bolesnika koji su uzimali ZDV/3TC/EFV, te 86% bolesnika koji su uzimali ZDV/3TC/ABC/EFV.
At week 48, 53.5% of all paediatric patients had a confirmed undetectable viral load &lt; 50 HIV-1 RNA copies/ml according to the TLOVR algorithm.
U 48. tjednu, 53,5% od svih pedijatrijskih bolesnika imalo je potvrđeno nemjerljivo virusno opterećenje &lt; 50 HIV-1 RNK kopija/ml prema TLOVR algoritmu.
At week 48, 89% (283/317) of patients randomised to switch to Eviplera at baseline (Eviplera) had HIV-1 RNA &lt; 50 copies/mL, 3% (8/317) were considered virologic failures (HIV RNA ≥ 50 copies/mL), and 8% (26/317) did not have data available in the week 48 window.
U 48. tjednu, 89% (283/317) pacijenata randomizirano za prebacivanje na lijek Eviplera na početku (Eviplera) imalo je HIV-1 RNK &lt; 50 kopija/ml, 3% (8/317) smatralo se virološkim neuspjehom (HIV RNK ≥50 kopija/ml), dok 8% (26/317) nije imalo dostupne podatke u 48. tjednu.
At Week 48, 89% (283/317) of patients randomised to switch to FTC/RPV/TDF had HIV-1 RNA
U 48. tjednu, 89% (283/317) bolesnika randomiziranih za prebacivanje na FTC/RPV/TDF imalo je HIV-1 RNK &lt; 50 kopija/ml, 3% (8/317) smatrano je virološkim neuspjesima (HIV RNK
At Week 48, 94% (46/49) of patients remained suppressed, and 4% (2/49) were considered virologic failures (HIV-1 RNA ≥ 50 copies/mL), and 1 patient (2%) had no data in the Week 48 window due to protocol violation with the last available HIV-1 RNA &lt; 50 copies/mL.
U 48. tjednu, 94% (46/49) bolesnika ostalo je suprimirano i 4% (2/49) smatrano je virološkim neuspjesima (HIV-1 RNK ≥ 50 kopija/ml), a 1 bolesnik (2%) nije imao podatke u okviru 48. tjedna zbog kršenja protokola s posljednjom dostupnom vrijednošću HIV-1 RNK &lt; 50 kopija/ml.
At week 48, in children aged 2 to 11 years old, no statistically significant difference was observed in the proportions of patients that achieved the primary endpoint of serum HBV DNA &lt; 1,000 copies/ml and normal ALT levels between the placebo arm and the adefovir dipivoxil arm.
U 48. tjednu, u djece u dobi od 2 do 11 godina, nije uočena statistički značajna razlika u udjelima pacijenata koji su postigli primarnu mjeru ishoda serumske HBV DNK &lt; 1000 kopija/ml i normalne razine ALT-a između skupine koja je primala placebo i one koja je primala adefovirdipivoksil.
At week 48, six adolescents in the tenofovir disoproxil fumarate group and one adolescent in the placebo group had significant lumbar spine BMD loss (defined as &gt; 4% loss).
U 48. tjednu 6 adolescenata u skupini koja je primala tenofovirdizoproksilfumarat i jedan adolescent iz skupine koja je primala placebo imali su značajan gubitak BMD-a u lumbalnoj kralježnici (definiran kao gubitak &gt; 4%).
At week 48, the virologic response, defined as the percentage of patients with confirmed plasma viral load &lt; 50 HIV-1 RNA copies/ml, was evaluated in 16 paediatric patients 15 kg to &lt; 20 kg and 5 paediatric patients 10 kg to &lt; 15 kg receiving
U tjednu 48, virološki odgovor, definiran kao postotak bolesnika s potvrđenim virusnim opterećenjem u plazmi &lt; 50 HIV-1 RNK kopija/ml, procijenjen je u 16 pedijatrijskih bolesnika u skupini 15 kg do &lt; 20 kg i 5 pedijatrijskih bolesnika u skupini 10 kg do
At Week 52, 42.9% of patients who received Humira/methotrexate combination therapy achieved clinical remission (DAS28 (CRP) &lt; 2.6) compared to 20.6% of patients receiving methotrexate monotherapy and 23.4% of patients receiving Humira monotherapy.
Nakon 52 tjedna liječenja, klinička remisija postignuta je u 42,9% bolesnika liječenih kombinacijom lijeka Humira i metotreksata (DAS28 [CRP] &lt; 2,6) u usporedbi s 20,6% bolesnika koji su dobivali monoterapiju metotreksatom, odnosno 23,4% bolesnika koji su dobivali monoterapiju lijekom Humira.